Economic Indicators - US stock index futures experienced a slight decline ahead of key economic data releases and a potential Supreme Court ruling on Trump's tariff policies [2][12] - The upcoming US Q4 GDP report is expected to show a growth of 2.5%, down from a previous 4.4% in Q3 [3][12] - The PCE price index is anticipated to rise by 2.8% year-over-year, with the core PCE expected to increase by 3% [3][12] - There is a division among Federal Reserve policymakers regarding concerns over the labor market and inflation, with inflation rates still above the Fed's 2% target [3][12] Market Reactions - The market is currently stagnant, awaiting catalysts such as the Supreme Court ruling and Nvidia's upcoming earnings report, which may induce volatility [4][13] - The S&P 500 index has remained flat year-to-date, while the Nasdaq index has seen a decline, indicating sector rotation and broadening market participation [4][13] Corporate Earnings and Performance - Grail's stock plummeted by 47% after its drug trial failed to meet primary endpoints [16] - Opendoor Technologies' stock surged by 19% following a Q4 revenue of $736 million, exceeding market expectations of $549 million [16] - Akamai Technologies' stock fell approximately 10% due to Q1 earnings guidance that did not meet expectations [16] - Comfort Systems reported a Q4 EPS of $9.37, surpassing expectations of $6.75, with revenue of $2.65 billion, significantly above the forecast of $2.34 billion [18] Tariff Impact on Businesses - JPMorgan's report indicates that US mid-sized businesses have been severely impacted by tariffs, with monthly tariff expenditures tripling since early 2025 [15] - Tariff expenditures account for about 10% of international spending for all mid-sized US businesses, rising to approximately 15% for those paying tariffs [15] - Research shows that US businesses and consumers bear 96% of the tariff costs, with 43% of these costs passed on to consumer prices [15][7] Commodity Prices - Goldman Sachs forecasts that gold prices will gradually rise to $5,400 per ounce by the end of 2026, driven by central bank demand and increased private investment [5][14]

Core Insights - The U.S. President Donald Trump claims that his tariff policy has prompted Swiss pharmaceutical giant Novartis to expand its production footprint in the U.S. [1][2] - Novartis CEO Vas Narasimhan informed Trump that the company is building new factories in the U.S. as a result of the tariff policy [1][2] Company Developments - Novartis has recently broken ground on production and R&D facilities in North Carolina and California, with plans to establish a new base in Florida and expand its radioligand therapy production network [1][2] - Last year, following threats of tariffs on imported drugs, Novartis announced a $23 billion investment to build and expand 10 facilities in the U.S. [1][2] Agreements and Pricing Strategy - Novartis reached an agreement with the White House aimed at lowering drug prices in the U.S., committing to launch new drugs at prices comparable to those in other developed countries [1][2] - The company plans to sell some treatment drugs directly to patients through government-supported platforms and seeks broader discounts for medical assistance while continuing to invest in U.S. production and R&D [1][2]

① 【三大期指齐涨】截至发稿，道指期货涨0.23%、标普500指数期货涨0.32%、纳指期货涨0.40%。 ②【美国银行据悉拟以250亿美元自有资金开展私募信贷业务】 当地时间2月19日，据媒体援引知情人 士透露，美国银行承诺投入250亿美元用于私募信贷交易，美国银行将利用自有资金投资私募信贷业 务，这是该公司现有直接贷款业务的延伸。该行计划通过隶属于其投资银行业务的资本市场部门发起这 些交易。截至发稿，美国银行上涨0.25%。 ③【埃森哲：管理层若不使用AI将无缘晋升】当地时间2月19日，据媒体报道，埃森哲（Accenture）已 明确告知资深员工，必须定期使用其内部AI工具，否则将失去晋升领导岗位的资格。副董事和高级经 理已被告知，"常规采用"AI是通往更高领导层的必经之路。公司不仅将AI使用情况作为考核指标，还开 始追踪员工每周登录AI工具（如AI Refinery和SynOps）的频率。出于合规和法律原因，欧洲12个国家 的员工以及处理美国政府合同的部门暂不受此政策影响。 ⑦ 【AppLovin计划推出自有社交网络】当地时间2月19日，Applovin首席产品与工程官Giovanni Ge在播 客节目 ...

Group 1 - US Bank plans to invest $25 billion in private credit transactions, extending its existing direct lending business through its capital markets division [2] - Accenture mandates senior employees to regularly use internal AI tools to qualify for promotions, tracking usage frequency as a performance metric [3] - Nvidia is close to finalizing a $30 billion investment in OpenAI, replacing a previous $100 billion long-term commitment [2] Group 2 - Meta has reduced equity-based awards for most employees by approximately 5%, marking the second consecutive year of cuts [2] - Newmont Corporation expects a 10% decrease in gold production by 2026 due to underperformance at two jointly operated mines with Barrick [2] - AppLovin is developing its own social network platform, which could enhance user data access and increase competition with established social media giants [3] Group 3 - AstraZeneca's Calquence combination therapy has been approved by the FDA for treating chronic lymphocytic leukemia and small lymphocytic lymphoma [3] - Google has released the Gemini 3.1 Pro model, which boasts double the inference performance compared to its predecessor [3]

Group 1 - US Bank plans to invest $25 billion in private credit transactions, extending its existing direct lending business through its capital markets division [2] - Accenture mandates senior employees to regularly use internal AI tools to qualify for promotions, tracking usage frequency as a performance metric [3] - Nvidia is nearing a $30 billion investment in OpenAI, replacing a previous $100 billion long-term commitment [2] Group 2 - Meta has reduced equity-based awards for most employees by approximately 5%, marking the second consecutive year of cuts [2] - Newmont Corporation expects a 10% decrease in gold production by 2026 due to underperformance at two jointly operated mines with Barrick [2] - AppLovin is developing its own social network platform, which could enhance user data access and increase competition with established social media giants [3] Group 3 - AstraZeneca's Calquence combination therapy has been approved by the FDA for treating chronic lymphocytic leukemia and small lymphocytic lymphoma [3] - Google has released the Gemini 3.1 Pro model, which boasts double the inference performance compared to its predecessor [3]

本文源自：金融界AI电报 据香港交易所披露，摩根大通对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2026年2 月12日从7.55%增至8.29%。 ...

【文/观察者网 王恺雯】德国总理默茨大年初一在社交媒体拜年，并预告将于近期访问中国。 德国媒体2月19日披露，默茨最近特意与数名中国问题专家共进晚餐，收集他们对此次访华行程的建 议。一名专家透露，默茨希望此行能和中国领导层建立联系。 据路透社报道，默茨18日在基民盟的一场活动上表示，他将在下周访问中国期间寻求合作机会。 默茨说，他此行的目标是讨论"欧洲和德国与中国之间未来的合作"。 "从战略上看，我们有兴趣在世界上寻找那些与我们志同道合、行事方式相近，尤其是愿意与我们共同 塑造未来的伙伴，从而使我们国家继续保持繁荣和高度社会保障。"默茨说。 德媒此前披露，默茨将于2月24日至27日访问中国。这是他去年5月上任以来首次访华。 伍德克是在华欧洲企业界具有影响力的代表人物，目前担任大成全球咨询公司–奥尔布赖特石桥集团 （DGA）合伙人。他认为，默茨此次访华的主要任务之一是为德国工业界争取更加公平的贸易环境。 另据德国《商报》的消息，此次默茨访华将有约30位企业高管随行，包括拜尔制药、大众汽车、西门 子、阿迪达斯、奔驰、汉高、DHL、德国商业银行、宝马、空客等公司。据悉，有意向随行的商界高 管人数远远超过30人。 德 ...

Group 1 - The pharmaceutical stocks have shown a general upward trend, with notable increases in companies such as Genscript Biotech (up 6.33%), Kintor Pharmaceutical (up 5.23%), and Junshi Biosciences (up 4.39%) [1] - The Chinese innovative drug licensing market has continued its strong growth into 2026, with total transaction amounts exceeding $33.28 billion in the first quarter, surpassing the highest quarterly upfront payment levels of 2025 [1] - According to Open Source Securities, the innovative drug sector has experienced a correction over the past two quarters, but long-term prospects for quality stocks are favorable, suggesting an increase in sector allocation focusing on companies with established overseas opportunities and high clinical data performance [1] Group 2 - Donghai Securities previously indicated that the innovative drug sector is entering a phase of accelerated profit realization by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceutical achieving profitability, while others like 3SBio and Shanghai Yizhong are expected to see significant performance increases [2] - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth, while external collaborations such as BD are crucial for enhancing earnings [2]

中国过去几年在大规模投资、庞大的人才库建设以及监管改革的加速推动下，生物技术生态体系蓬勃发 展，并迅速崛起为创新药强国。 他表示，美国在新药研究的一期临床试验方面受制于严格的流程，落后于中国。在2月18日发表在《新 英格兰医学杂志》（NEJM）上发表的一篇文章中，马卡里指出，FDA未来审批新药，只需要基于一项 关键临床试验，而不再需要沿用六十多年来的"双试验"的黄金标准。 自1960年代以来，FDA在审批新药时至少要求进行两项大规模、长周期的临床试验，以确认临床研究结 果并非偶然，具备可重复性。不过，过去五年来，FDA已经默认在一些肿瘤药及罕见病药物审批中采用 单项研究作为依据，约有60%的新药凭借单项临床研究获批。 马卡里在文章里算了一笔经济账。他表示，现在做新药研发，动辄烧掉十几亿美元，很大一部分砸在临 床试验上。FDA认为，单项试验能实质性降低药企的研发成本，这会带来药物开发的激增。 中国过去几年在大规模投资、庞大的人才库建设以及监管改革的加速推动下，生物技术生态体系蓬勃发 展，并迅速崛起为创新药强国。 摩根士丹利的数据显示，中国目前正在进行的临床试验比美国多，占全球新药批准的近三分之一。 相比之下，美 ...

Core Viewpoint - The announcement of the clinical development of ASC36, a novel oral glucagon-like peptide-1 (GLP-1) receptor agonist, marks a significant advancement for the company in the metabolic disease sector, showcasing its proprietary oral peptide delivery enhancement technology [1] Company Summary - The company's stock, Gilead Sciences-B (01672), saw an increase of nearly 8%, with a current price of HKD 17.72 and a trading volume of HKD 36.79 million [1] - The board of directors has selected ASC36 for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is developed using the company's AI-assisted drug discovery technology (AISBDD), representing a key transition from platform capability to candidate drug [1]